5 SIMPLE STATEMENTS ABOUT ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS EXPLAINED

In Phase C, members will obtain ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment till sickness progression or even the individuals are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit goods within three days before the very first dose